We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $1.06B
1-Year Est. Return 52.03%
This Fund
S&P 500
This Quarter Est. Return
+22.03%
1 Year Est. Return
+52.03%
3 Year Est. Return
+131.18%
5 Year Est. Return
+187.67%
10 Year Est. Return
+1,140.82%
AUM
$1.06B
AUM Growth
+$249M
Cap. Flow
+$137M
Cap. Flow %
12.89%
Top 10 Hldgs %
25.08%
Holding
106
New
20
Increased
41
Reduced
34
Closed
7

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$28.5M
2
MRK icon
Merck
MRK
+$25M
3
UNH icon
UnitedHealth
UNH
+$17.8M
4
JNJ icon
Johnson & Johnson
JNJ
+$16.9M
5
CNC icon
Centene
CNC
+$13M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$14.1M
2
LLY icon
Eli Lilly
LLY
+$11.6M
3
VEEV icon
Veeva Systems
VEEV
+$11.2M
4
ADPT icon
Adaptive Biotechnologies
ADPT
+$9.99M
5
BSX icon
Boston Scientific
BSX
+$9.48M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UNH icon
1
UnitedHealth
UNH
$338B
$38.9M 3.67%
93,600
+48,100
+106% +$17.8M
CVS icon
2
CVS Health
CVS
$114B
$28.9M 2.73%
279,374
-57,126
-17% -$5.1M
AZN icon
3
AstraZeneca
AZN
$258B
$28.5M 2.69%
+151,500
New +$28.5M
MRK icon
4
Merck
MRK
$367B
$27.4M 2.59%
+213,500
New +$25M
LLY icon
5
Eli Lilly
LLY
$1.05T
$26.8M 2.53%
22,315
-11,400
-34% -$11.6M
ABBV icon
6
AbbVie
ABBV
$467B
$24.4M 2.3%
96,775
+25,200
+35% +$5.42M
ALHC icon
7
Alignment Healthcare
ALHC
$1.7B
$23.7M 2.24%
997,083
-56,367
-5% -$1.08M
EW icon
8
Edwards Lifesciences
EW
$49.7B
$23.5M 2.22%
260,000
+97,000
+60% +$8.13M
GILD icon
9
Gilead Sciences
GILD
$187B
$22.5M 2.13%
178,250
+10,500
+6% +$1.38M
JAZZ icon
10
Jazz Pharmaceuticals
JAZZ
$15.4B
$21.1M 1.99%
87,440
+11,550
+15% +$2.53M
BIIB icon
11
Biogen
BIIB
$33.6B
$20.5M 1.93%
94,850
-14,250
-13% -$2.73M
SYK icon
12
Stryker
SYK
$104B
$20.5M 1.93%
65,000
+17,200
+36% +$5.42M
BSX icon
13
Boston Scientific
BSX
$63.7B
$19.2M 1.81%
450,500
-174,500
-28% -$9.48M
JNJ icon
14
Johnson & Johnson
JNJ
$654B
$18.4M 1.74%
+72,500
New +$16.9M
GH icon
15
Guardant Health
GH
$23.8B
$17.3M 1.63%
115,000
-30,000
-21% -$3.26M
REGN icon
16
Regeneron Pharmaceuticals
REGN
$81.1B
$17.1M 1.61%
27,390
-20,710
-43% -$14.1M
GKOS icon
17
Glaukos
GKOS
$9.11B
$16.6M 1.57%
119,000
+35,000
+42% +$4.43M
BMRN icon
18
BioMarin Pharmaceuticals
BMRN
$11.7B
$16.6M 1.57%
290,500
+83,500
+40% +$4.57M
NRIX icon
19
Nurix Therapeutics
NRIX
$2.39B
$16.6M 1.57%
684,250
+370,750
+118% +$6.32M
NTRA icon
20
Natera
NTRA
$59.5B
$16.6M 1.56%
61,050
+9,450
+18% +$2.01M
MIRM icon
21
Mirum Pharmaceuticals
MIRM
$5.82B
$16.3M 1.54%
139,205
+46,600
+50% +$4.68M
INSM icon
22
Insmed
INSM
$25.7B
$16.2M 1.53%
151,960
-7,800
-5% -$944K
THC icon
23
Tenet Healthcare
THC
$20.9B
$15.9M 1.5%
85,200
+31,200
+58% +$5.74M
TMO icon
24
Thermo Fisher Scientific
TMO
$250B
$15.8M 1.49%
31,580
-9,760
-24% -$4.69M
CNC icon
25
Centene
CNC
$30.5B
$15.7M 1.48%
+244,000
New +$13M
1
2 3 4 5

Similar funds

JSC
J. Stern & Co London, United Kingdom $1.06B AUM 11.76% 1-Year Est. Return
PCI
Planning Center Inc Moline, Illinois $1.06B AUM 12.82% 1-Year Est. Return
SAM
Synergy Asset Management Vancouver, Washington $1.06B AUM 36.26% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
BDP
Brehaut David Pascal $1.06B AUM
GX
Greylock XIV Menlo Park, California $1.06B AUM
CIC
Cutler Investment Counsel Jacksonville, Oregon $1.06B AUM 20.29% 1-Year Est. Return
RCIM
Red Cedar Investment Management Grand Rapids, Michigan $1.06B AUM 30.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2026 Portfolio in Review

As of Q2 2026, Rhenman & Partners Asset Management held 106 positions worth $1.06B, up 31% from $810M the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Rhenman & Partners Asset Management deployed $137M of net new capital in Q2 2026, opening 20 new positions and adding to 41 existing holdings. Its largest new stake was AstraZeneca: 151,500 shares worth $28.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $14.1M trimmed.

  • Rhenman & Partners Asset Management's largest Q2 2026 buy was AstraZeneca: 151,500 shares worth $28.5M.
  • Rhenman & Partners Asset Management added most to UnitedHealth in Q2 2026, an estimated $17.8M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2026 reduction was Regeneron Pharmaceuticals, cutting an estimated $14.1M.
  • Rhenman & Partners Asset Management fully exited Adaptive Biotechnologies in Q2 2026, selling an estimated $9.99M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 25% of its $1.06B portfolio in Q2 2026.
  • Rhenman & Partners Asset Management opened 20 new positions and closed 7 in Q2 2026.
  • Rhenman & Partners Asset Management's portfolio value rose 31% quarter-over-quarter to $1.06B.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.